Published in J Thromb Haemost on September 01, 2006
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med (2007) 2.85
Arterial thrombosis--insidious, unpredictable and deadly. Nat Med (2011) 1.96
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood (2008) 1.93
Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. Blood (2009) 1.57
Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. Blood (2015) 1.44
Lysyl oxidase is associated with increased thrombosis and platelet reactivity. Blood (2016) 1.41
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Platelet adhesion under flow. Microcirculation (2009) 1.31
Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood (2013) 1.30
Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood (2006) 1.22
Aegyptin displays high-affinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation in vivo. FEBS J (2009) 1.01
The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice. Blood (2007) 0.95
Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia. Arterioscler Thromb Vasc Biol (2008) 0.92
RhoG protein regulates platelet granule secretion and thrombus formation in mice. J Biol Chem (2013) 0.90
Polymicrobial sepsis and endotoxemia promote microvascular thrombosis via distinct mechanisms. J Thromb Haemost (2010) 0.90
Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice. Platelets (2012) 0.88
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood (2014) 0.88
Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood (2009) 0.87
Evaluation of the physiological significance of botrocetin/ von Willebrand factor in vitro signaling. J Thromb Haemost (2008) 0.84
Aspirin: pharmacology and clinical applications. Thrombosis (2011) 0.83
Fibrin activates GPVI in human and mouse platelets. Blood (2015) 0.79
Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. Arterioscler Thromb Vasc Biol (2014) 0.79
α2β1 integrin, GPVI receptor, and common FcRγ chain on mouse platelets mediate distinct responses to collagen in models of thrombosis. PLoS One (2014) 0.76
The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA (1989) 12.07
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem (1994) 6.31
Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell (1996) 5.12
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell (1998) 4.18
Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A (2001) 3.07
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Platelets have more than one binding site for von Willebrand factor. J Clin Invest (1983) 2.89
Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest (1980) 2.88
Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A (1977) 2.83
The complex multimeric composition of factor VIII/von Willebrand factor. Blood (1981) 2.76
Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem (1991) 2.52
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 2.38
Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Regul (1990) 2.29
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem (1985) 2.23
Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A (1990) 2.23
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A (1983) 2.20
Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol (2001) 2.14
Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med (1986) 2.08
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood (2000) 2.05
Echocardiographic measurements in normal subjects. Growth-related changes that occur between infancy and early adulthood. Circulation (1978) 2.05
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem (1988) 2.04
Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci U S A (1982) 2.02
Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A (2000) 1.94
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem (1989) 1.92
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell (1989) 1.92
A model for predicting the counseling practices of physicians. J Gen Intern Med (1986) 1.91
Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest (1986) 1.89
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1986) 1.85
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol (1982) 1.77
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol (2001) 1.74
Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci U S A (1987) 1.73
von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem (1986) 1.71
Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem (1992) 1.70
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest (1996) 1.65
Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A (1988) 1.64
Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem (1987) 1.63
A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. Br Med J (Clin Res Ed) (1985) 1.62
The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem (1986) 1.62
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene (1987) 1.60
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem (1996) 1.57
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest (1995) 1.52
Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost (2009) 1.51
Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood (1998) 1.51
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest (1984) 1.50
Type 1 plasminogen activator inhibitor. Prog Hemost Thromb (1989) 1.49
Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation (2000) 1.48
Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem (1991) 1.48
Utilization of information technology in medical education: a questionnaire survey of students in a Malaysian institution. Med J Malaysia (2002) 1.48
von Willebrand factor. FASEB J (1993) 1.47
Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets. Am J Hematol (1990) 1.46
Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med (1995) 1.46
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A (1985) 1.46
Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol (1993) 1.45
Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest (1985) 1.44
Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A (1998) 1.44
Callosal dysgenesis in fetuses with ventriculomegaly: levels of agreement between imaging modalities and postnatal outcome. Ultrasound Obstet Gynecol (2012) 1.44
Cloning of thermostable DNA polymerases from hyperthermophilic marine Archaea with emphasis on Thermococcus sp. 9 degrees N-7 and mutations affecting 3'-5' exonuclease activity. Proc Natl Acad Sci U S A (1996) 1.42
Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics (2000) 1.42
Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest (1991) 1.41
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest (2001) 1.41
Somatostatin and variceal haemorrhage. Lancet (1984) 1.40
Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest (1998) 1.40
Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation (2001) 1.39
Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem (1988) 1.35
Shear stress induction of the tissue factor gene. J Clin Invest (1997) 1.35
Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest (1989) 1.33
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood (1998) 1.29
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa. J Biol Chem (1993) 1.29
von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest (1986) 1.28
Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem (1995) 1.27
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J Clin Invest (1992) 1.26
Asymptomatic liver disease in haemophiliacs. J Clin Pathol (1975) 1.26
The fibrinolytic system of the vascular wall. Clin Haematol (1985) 1.25
Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood (1993) 1.25
Tissue distribution of factor VIII gene expression in vivo--a closer look. Thromb Haemost (2001) 1.24
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol (2001) 1.23
Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody. J Clin Invest (1985) 1.23
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A (1999) 1.23